{
  "pmcid": "PMC5561238",
  "pmid": "28819312",
  "title": "Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles",
  "overall_score": 0.23289665645129923,
  "num_benchmarks": 4,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 44,
        "items": [
          {
            "variant": "HLA-C*04:01",
            "gene": "HLA-C",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "HLA-C*04:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Carriage of HLA-C*04:01 was the only allele with a consistent, significant predisposing relationship for cutaneous nevirapine hypersensitivity rash across all ancestral groups. Whole cohort OR = 3.06, P = 0.0001 (ethnicity-adjusted); Asian OR = 5.49, P = 0.0001; Caucasian OR = 2.08, P = 0.02; African OR = 3.84, P = 0.04. In multivariate models, OR = 4.06 [2.39\u20136.88].",
              "Sentence": "Genotype HLA-C*04:01 Is Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-HLA-C*04:01 carriers.",
              "Alleles": "HLA-C*04:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-HLA-C*04:01 carriers",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Four digit HLA typing was available for 151 cases and 413 controls. In single allele logistic regression analyses *HLA-C*04:01* was the only allele for which a consistent, significant predisposing relationship for cutaneous manifestations of NVP HSR was observed across all ancestral groups (Odds ratio (OR) = 3.06 and *P* = 0.0001 in whole cohort analysis, (Fig. [1A](#Fig1)); Asian: OR = 5.49, *P* = 0.0001; Caucasian: OR = 2.08, *P* = 0.02; and African: OR = 3.84, *P* = 0.04).\"",
                "\"### Overall model and risk assessment for cutaneous NVP HSR\n\nMultivariate modelling was used to examine overall risk for cutaneous NVP HSR associated with the identified predisposing and protective clusters in both whole-cohort and ancestry-specific analyses. ...\n\n### Table 2.\n\n|   | ALL OR [95% CI] | Caucasian OR [95% CI] | Asian OR [95% CI] | African OR [95% CI] |\n| --- | --- | --- | --- | --- |\n| HLA-C*04:01 | 4.06 [2.39\u20136.88] | 3.14 [1.49\u20136.62] | 7.30 [2.74\u201319.5] | 5.60 [1.22\u201325.75] |\"",
                "\"Both *HLA-C*04* and *HLA-B*35* have been linked with cutaneous NVP HSR symptoms of varying severity in other studies^19, 21, 22, 46\u201348^, but with *HLA-B*35*/*-C*04* carried as a common haplotype it has been difficult to disentangle the relative contributions of the individual alleles. Our data suggest that *HLA-B*35:05* and *HLA-C*04:01* may have a synergistic effect in South East Asians, but any apparent predisposition conferred by other *HLA-B*35* alleles is abrogated when co-carriage of a risk *HLA-C* allele is considered. Moreover, here we demonstrate that the observed association with *HLA-C*04* across ethnicities is primarily driven by the unique F pocket motif that *HLA-C*04:01* shares with *HLA-C*05:01* and *HLA-C*18:01* which have dominant effects observed in the Hispanic and African subgroups, respectively.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-C*04:01",
                "variant_id": "PA165957046",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "HLA-C*05:01",
            "gene": "HLA-C",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "HLA-C*05:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "In Caucasians, HLA-C*05:01 carriage vs non-carriage was associated with cutaneous nevirapine hypersensitivity rash (OR = 2.84, P = 0.002). Multivariable OR for C*05:01/09 within the risk F-pocket cluster was 2.2 [1.2\u20133.9].",
              "Sentence": "Genotype HLA-C*05:01 Is Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-HLA-C*05:01 carriers.",
              "Alleles": "HLA-C*05:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-HLA-C*05:01 carriers",
              "Comparison Metabolizer types": null,
              "Citations": [
                "However, analyses specific to ancestral groups also revealed several other *HLA-C* allelic associations indicative of HSR predisposition, namely *HLA-C*05:01* in Caucasians (versus non-*HLA-C*05:01* carriers: OR = 2.84, *P* = 0.002) and *HLA-C*18:01* in patients with African ancestry (versus non-*HLA-C*18:01* carriers: OR = 2.67, *P* = 0.2; vs non-*HLA-C*04:01*/*-C*18:01* carriers: OR = 4.71, *P* = 0.06).",
                "Moreover, here we demonstrate that the observed association with *HLA-C*04* across ethnicities is primarily driven by the unique F pocket motif that *HLA-C*04:01* shares with *HLA-C*05:01* and *HLA-C*18:01* which have dominant effects observed in the Hispanic and African subgroups, respectively.",
                "...we note relative size of observed risk effects reflect the ordering of imputed expression levels^28\u201330^ (MFI expression units: *C*05:01* = 154 < *C*04:01* = 199 < *C*18:01* = 239; multivariable OR[95% CI]: *C*05:01*/09 = 2.2[1.2\u20133.9] < *C*04:01*/03/06 = 2.5[1.6\u20133.9] < *C*18:01* = 2.6[0.6\u201311.1])."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-C*05:01",
                "variant_id": "PA165957192",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "HLA-C*18:01",
            "gene": "HLA-C",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "HLA-C*18:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "In patients of African ancestry, HLA-C*18:01 showed predisposition to cutaneous nevirapine hypersensitivity. Versus non-HLA-C*18:01 carriers: OR = 2.67, P = 0.2; versus non-HLA-C*04:01/*-C*18:01 carriers: OR = 4.71, P = 0.06. In multivariate F-pocket cluster analysis, OR for C*18:01 was 2.6 [0.6\u201311.1], and the broader non-C*04:01 risk F-pocket cluster showed OR 2.91 [1.62\u20135.23].",
              "Sentence": "Genotype HLA-C*18:01 Is Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-HLA-C*18:01 carriers.",
              "Alleles": "HLA-C*18:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-HLA-C*18:01 carriers",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cHowever, analyses specific to ancestral groups also revealed several other *HLA-C* allelic associations indicative of HSR predisposition, namely *HLA-C*05:01* in Caucasians (versus non-*HLA-C*05:01* carriers: OR = 2.84, *P* = 0.002) and *HLA-C*18:01* in patients with African ancestry (versus non-*HLA-C*18:01* carriers: OR = 2.67, *P* = 0.2; vs non-*HLA-C*04:01*/*-C*18:01* carriers: OR = 4.71, *P* = 0.06).\u201d",
                "\u201cMoreover, here we demonstrate that the observed association with *HLA-C*04* across ethnicities is primarily driven by the unique F pocket motif that *HLA-C*04:01* shares with *HLA-C*05:01* and *HLA-C*18:01* which have dominant effects observed in the Hispanic and African subgroups, respectively.\u201d",
                "\u201cIn summary, this study has considered how peptide binding chemistry of the HLA antigen binding groove impacts cutaneous NVP HSR and has identified the unique F pocket conformation that defines a primary risk cluster of *HLA-C* alleles.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-C*18:01",
                "variant_id": "PA165958003",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "HLA-C*04:03",
            "gene": "HLA-C",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "HLA-C*04:03",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Alleles sharing the primary risk F-pocket motif DNKLYLRNFYWTKW (HLA-C*04:03/06/07, C*05:01/09, C*18:01) formed a risk cluster for cutaneous nevirapine hypersensitivity. In multivariate modelling, this \"other risk F pocket\" cluster excluding HLA-C*04:01 had OR 2.91 [1.62\u20135.23] overall; Caucasian OR 3.92 [1.74\u20138.86].",
              "Sentence": "Genotypes HLA-C*04:03 + HLA-C*04:06 + HLA-C*04:07 + HLA-C*05:09 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to carriers of HLA-C alleles without the risk F-pocket motif.",
              "Alleles": "HLA-C*04:03 + HLA-C*04:06 + HLA-C*04:07 + HLA-C*05:09",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "HLA-C alleles lacking the risk F-pocket motif",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"For every pocket, the characteristic *HLA-C*04:01* motif demonstrated greatest impact on development of cutaneous NVP HSR (Fig. [1B](#Fig1)), with the greatest significance attributable to the F pocket^4^, where commonality of the residues Asp74-Asn77-Lys80-Leu81-Tyr84-Leu95-Arg97-Asn114-Phe116-Tyr123-Trp133-Thr143-Lys146-Trp147 grouped risk alleles *HLA-C*05:01* and *HLA-C*18:01* with *HLA-C*04:01* in a cluster that also included *HLA-C*-04:03* and -*04:06* (Fig. [1C](#Fig1)).\"",
                "\"Moreover, here we demonstrate that the observed association with *HLA-C*04* across ethnicities is primarily driven by the unique F pocket motif that *HLA-C*04:01* shares with *HLA-C*05:01* and *HLA-C*18:01* which have dominant effects observed in the Hispanic and African subgroups, respectively.\"",
                "\"Other risk F pocket (DNKLYLRNFYWTKW) HLA-C*04:(03/06/07), -C*05:(01/09), -C*18:01 | 2.91 [1.62\u20135.23] | 3.92 [1.74\u20138.86] | 1.64 [0.53\u20135.12] | 3.18 [0.53\u201319.04]\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-C*04:03, HLA-C*04:06, HLA-C*04:07, HLA-C*05:09",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-C*04:06",
            "gene": "HLA-C",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "HLA-C*04:06",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Alleles sharing the primary risk F-pocket motif DNKLYLRNFYWTKW (HLA-C*04:03/06/07, C*05:01/09, C*18:01) formed a risk cluster for cutaneous nevirapine hypersensitivity. In multivariate modelling, this \"other risk F pocket\" cluster excluding HLA-C*04:01 had OR 2.91 [1.62\u20135.23] overall; Caucasian OR 3.92 [1.74\u20138.86].",
              "Sentence": "Genotypes HLA-C*04:03 + HLA-C*04:06 + HLA-C*04:07 + HLA-C*05:09 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to carriers of HLA-C alleles without the risk F-pocket motif.",
              "Alleles": "HLA-C*04:03 + HLA-C*04:06 + HLA-C*04:07 + HLA-C*05:09",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "HLA-C alleles lacking the risk F-pocket motif",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"For every pocket, the characteristic *HLA-C*04:01* motif demonstrated greatest impact on development of cutaneous NVP HSR (Fig. [1B](#Fig1)), with the greatest significance attributable to the F pocket^4^, where commonality of the residues Asp74-Asn77-Lys80-Leu81-Tyr84-Leu95-Arg97-Asn114-Phe116-Tyr123-Trp133-Thr143-Lys146-Trp147 grouped risk alleles *HLA-C*05:01* and *HLA-C*18:01* with *HLA-C*04:01* in a cluster that also included *HLA-C*-04:03* and -*04:06* (Fig. [1C](#Fig1)).\"",
                "\"Moreover, here we demonstrate that the observed association with *HLA-C*04* across ethnicities is primarily driven by the unique F pocket motif that *HLA-C*04:01* shares with *HLA-C*05:01* and *HLA-C*18:01* which have dominant effects observed in the Hispanic and African subgroups, respectively.\"",
                "\"Other risk F pocket (DNKLYLRNFYWTKW) HLA-C*04:(03/06/07), -C*05:(01/09), -C*18:01 | 2.91 [1.62\u20135.23] | 3.92 [1.74\u20138.86] | 1.64 [0.53\u20135.12] | 3.18 [0.53\u201319.04]\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-C*04:03, HLA-C*04:06, HLA-C*04:07, HLA-C*05:09",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-C*04:07",
            "gene": "HLA-C",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "HLA-C*04:07",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Alleles sharing the primary risk F-pocket motif DNKLYLRNFYWTKW (HLA-C*04:03/06/07, C*05:01/09, C*18:01) formed a risk cluster for cutaneous nevirapine hypersensitivity. In multivariate modelling, this \"other risk F pocket\" cluster excluding HLA-C*04:01 had OR 2.91 [1.62\u20135.23] overall; Caucasian OR 3.92 [1.74\u20138.86].",
              "Sentence": "Genotypes HLA-C*04:03 + HLA-C*04:06 + HLA-C*04:07 + HLA-C*05:09 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to carriers of HLA-C alleles without the risk F-pocket motif.",
              "Alleles": "HLA-C*04:03 + HLA-C*04:06 + HLA-C*04:07 + HLA-C*05:09",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "HLA-C alleles lacking the risk F-pocket motif",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"For every pocket, the characteristic *HLA-C*04:01* motif demonstrated greatest impact on development of cutaneous NVP HSR (Fig. [1B](#Fig1)), with the greatest significance attributable to the F pocket^4^, where commonality of the residues Asp74-Asn77-Lys80-Leu81-Tyr84-Leu95-Arg97-Asn114-Phe116-Tyr123-Trp133-Thr143-Lys146-Trp147 grouped risk alleles *HLA-C*05:01* and *HLA-C*18:01* with *HLA-C*04:01* in a cluster that also included *HLA-C*-04:03* and -*04:06* (Fig. [1C](#Fig1)).\"",
                "\"Moreover, here we demonstrate that the observed association with *HLA-C*04* across ethnicities is primarily driven by the unique F pocket motif that *HLA-C*04:01* shares with *HLA-C*05:01* and *HLA-C*18:01* which have dominant effects observed in the Hispanic and African subgroups, respectively.\"",
                "\"Other risk F pocket (DNKLYLRNFYWTKW) HLA-C*04:(03/06/07), -C*05:(01/09), -C*18:01 | 2.91 [1.62\u20135.23] | 3.92 [1.74\u20138.86] | 1.64 [0.53\u20135.12] | 3.18 [0.53\u201319.04]\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-C*04:03, HLA-C*04:06, HLA-C*04:07, HLA-C*05:09",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-C*05:09",
            "gene": "HLA-C",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "HLA-C*05:09",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Alleles sharing the primary risk F-pocket motif DNKLYLRNFYWTKW (HLA-C*04:03/06/07, C*05:01/09, C*18:01) formed a risk cluster for cutaneous nevirapine hypersensitivity. In multivariate modelling, this \"other risk F pocket\" cluster excluding HLA-C*04:01 had OR 2.91 [1.62\u20135.23] overall; Caucasian OR 3.92 [1.74\u20138.86].",
              "Sentence": "Genotypes HLA-C*04:03 + HLA-C*04:06 + HLA-C*04:07 + HLA-C*05:09 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to carriers of HLA-C alleles without the risk F-pocket motif.",
              "Alleles": "HLA-C*04:03 + HLA-C*04:06 + HLA-C*04:07 + HLA-C*05:09",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "HLA-C alleles lacking the risk F-pocket motif",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"For every pocket, the characteristic *HLA-C*04:01* motif demonstrated greatest impact on development of cutaneous NVP HSR (Fig. [1B](#Fig1)), with the greatest significance attributable to the F pocket^4^, where commonality of the residues Asp74-Asn77-Lys80-Leu81-Tyr84-Leu95-Arg97-Asn114-Phe116-Tyr123-Trp133-Thr143-Lys146-Trp147 grouped risk alleles *HLA-C*05:01* and *HLA-C*18:01* with *HLA-C*04:01* in a cluster that also included *HLA-C*-04:03* and -*04:06* (Fig. [1C](#Fig1)).\"",
                "\"Moreover, here we demonstrate that the observed association with *HLA-C*04* across ethnicities is primarily driven by the unique F pocket motif that *HLA-C*04:01* shares with *HLA-C*05:01* and *HLA-C*18:01* which have dominant effects observed in the Hispanic and African subgroups, respectively.\"",
                "\"Other risk F pocket (DNKLYLRNFYWTKW) HLA-C*04:(03/06/07), -C*05:(01/09), -C*18:01 | 2.91 [1.62\u20135.23] | 3.92 [1.74\u20138.86] | 1.64 [0.53\u20135.12] | 3.18 [0.53\u201319.04]\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-C*04:03, HLA-C*04:06, HLA-C*04:07, HLA-C*05:09",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*35:05",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "HLA-B*35:05",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The most prominent HLA-B risk motif was the E pocket sequence Ser97-Asp114-Trp147-Val152-Leu156 uniquely carried by HLA-B*35:05. In this cohort, HLA-B*35:05 was present in 9 of 10 Southeast Asian cutaneous nevirapine hypersensitivity cases on a haplotype with HLA-C*04:01, suggesting synergistic risk. Included among \"risk B07 alleles\" with overall OR 2.32 [1.42\u20133.79].",
              "Sentence": "Genotype HLA-B*35:05 Is Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-HLA-B*35:05 carriers.",
              "Alleles": "HLA-B*35:05",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-HLA-B*35:05 carriers",
              "Comparison Metabolizer types": null,
              "Citations": [
                "The most prominent HLA-B motif associated with risk for cutaneous NVP HSR was the E pocket sequence Ser97-Asp114-Trp147-Val152-Leu156 uniquely carried by *HLA-B*35:05* (Fig. [2A](#Fig2), Table [S3](#MOESM1)). Notably, all other *HLA-B*35* alleles lack the Ser97 residue and significant predisposition did not extend to the *HLA-B*35* allelic group considered as a whole (Table [1](#Tab1)). In this cohort, haplotypic *HLA-C*04:01* is carried with *HLA-B*35:05* in 9 of 10 Southeast Asian cutaneous NVP HSR cases so it is possible that the alleles may act synergistically.",
                "Risk *HLA-B* and *HLA-DRB1* alleles are shared across several *HLA-C* allele groups in addition to the *HLA-C*04:01* F pocket risk group and there is little support for any dominant haplotypic effect in cutaneous NVP HSR risk with the exception of *HLA-B*35:05* carried with *HLA-C*04:01* in Asians which display strong linkage disequilibrium.",
                "Risk B07 alleles HLA-B*35:05, -B*39:10, -B*51:(01/02), -B*54:01, HLA-B*55:(01/02), -B*56:(01/04), -B*67:01, HLA-B*78:01 | 2.32 [1.42\u20133.79] | 2.27 [1.06\u20134.85] | 2.19 [1.10\u20134.35] | 2.93 [0.23\u201337.10]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*35:05",
                "variant_id": "PA165955262",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "HLA-B*15:01",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "HLA-B*15:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A protective effect for cutaneous nevirapine hypersensitivity was associated with a cluster of HLA-B B62 supertype alleles defined by the B-pocket motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99. Protective alleles were HLA-B*15:01/12/24/25/27/32/35 and HLA-B*52:01. In multivariate models, \"Protective HLA-B alleles\" had OR 0.18 [0.07\u20130.46] overall; Asian OR 0.18 [0.05\u20130.61].",
              "Sentence": "Genotypes HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01 Are Not associated with increased and instead are associated with decreased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of the protective HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cThe most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001 and OR = 0.20, p = 0.0003 for models with and without adjustment for the primary HLA-C cluster) (Fig. 2A). The B pocket4, 5 motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99 is characteristic of a cluster of HLA-B B62 supertype alleles: HLA-B*15:(01/12/24/25/27/35) and HLA-B*52:01 (Figure S3 and Table S2), consistent with a previously reported protective HLA-B*15 association with cutaneous NVP reactions observed in an Indian population34.\u201d",
                "\u201cProtective HLA-B alleles HLA-B*15:(01/12/24/25/27/32/35), -B*52:01 0.18 [0.07\u20130.46] \u2026 Asian OR [95% CI] 0.18 [0.05\u20130.61]\u201d",
                "\u201cSimilarly, protection afforded by the protective HLA-B*15:01/-B*52:01 cluster could be explained by dominance of the more highly expressed HLA-B molecules. In the case of protective HLA-B alleles the particular HLA-B-drug\u2014peptide combination may mimic a self-peptide-HLA combination that is tolerated by the host.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*15:01, HLA-B*15:12, HLA-B*15:24, HLA-B*15:25, HLA-B*15:27, HLA-B*15:32, HLA-B*15:35, HLA-B*52:01",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*15:12",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "HLA-B*15:12",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A protective effect for cutaneous nevirapine hypersensitivity was associated with a cluster of HLA-B B62 supertype alleles defined by the B-pocket motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99. Protective alleles were HLA-B*15:01/12/24/25/27/32/35 and HLA-B*52:01. In multivariate models, \"Protective HLA-B alleles\" had OR 0.18 [0.07\u20130.46] overall; Asian OR 0.18 [0.05\u20130.61].",
              "Sentence": "Genotypes HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01 Are Not associated with increased and instead are associated with decreased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of the protective HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cThe most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001 and OR = 0.20, p = 0.0003 for models with and without adjustment for the primary HLA-C cluster) (Fig. 2A). The B pocket4, 5 motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99 is characteristic of a cluster of HLA-B B62 supertype alleles: HLA-B*15:(01/12/24/25/27/35) and HLA-B*52:01 (Figure S3 and Table S2), consistent with a previously reported protective HLA-B*15 association with cutaneous NVP reactions observed in an Indian population34.\u201d",
                "\u201cProtective HLA-B alleles HLA-B*15:(01/12/24/25/27/32/35), -B*52:01 0.18 [0.07\u20130.46] \u2026 Asian OR [95% CI] 0.18 [0.05\u20130.61]\u201d",
                "\u201cSimilarly, protection afforded by the protective HLA-B*15:01/-B*52:01 cluster could be explained by dominance of the more highly expressed HLA-B molecules. In the case of protective HLA-B alleles the particular HLA-B-drug\u2014peptide combination may mimic a self-peptide-HLA combination that is tolerated by the host.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*15:01, HLA-B*15:12, HLA-B*15:24, HLA-B*15:25, HLA-B*15:27, HLA-B*15:32, HLA-B*15:35, HLA-B*52:01",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*15:24",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "HLA-B*15:24",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A protective effect for cutaneous nevirapine hypersensitivity was associated with a cluster of HLA-B B62 supertype alleles defined by the B-pocket motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99. Protective alleles were HLA-B*15:01/12/24/25/27/32/35 and HLA-B*52:01. In multivariate models, \"Protective HLA-B alleles\" had OR 0.18 [0.07\u20130.46] overall; Asian OR 0.18 [0.05\u20130.61].",
              "Sentence": "Genotypes HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01 Are Not associated with increased and instead are associated with decreased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of the protective HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cThe most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001 and OR = 0.20, p = 0.0003 for models with and without adjustment for the primary HLA-C cluster) (Fig. 2A). The B pocket4, 5 motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99 is characteristic of a cluster of HLA-B B62 supertype alleles: HLA-B*15:(01/12/24/25/27/35) and HLA-B*52:01 (Figure S3 and Table S2), consistent with a previously reported protective HLA-B*15 association with cutaneous NVP reactions observed in an Indian population34.\u201d",
                "\u201cProtective HLA-B alleles HLA-B*15:(01/12/24/25/27/32/35), -B*52:01 0.18 [0.07\u20130.46] \u2026 Asian OR [95% CI] 0.18 [0.05\u20130.61]\u201d",
                "\u201cSimilarly, protection afforded by the protective HLA-B*15:01/-B*52:01 cluster could be explained by dominance of the more highly expressed HLA-B molecules. In the case of protective HLA-B alleles the particular HLA-B-drug\u2014peptide combination may mimic a self-peptide-HLA combination that is tolerated by the host.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*15:01, HLA-B*15:12, HLA-B*15:24, HLA-B*15:25, HLA-B*15:27, HLA-B*15:32, HLA-B*15:35, HLA-B*52:01",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*15:25",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "HLA-B*15:25",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A protective effect for cutaneous nevirapine hypersensitivity was associated with a cluster of HLA-B B62 supertype alleles defined by the B-pocket motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99. Protective alleles were HLA-B*15:01/12/24/25/27/32/35 and HLA-B*52:01. In multivariate models, \"Protective HLA-B alleles\" had OR 0.18 [0.07\u20130.46] overall; Asian OR 0.18 [0.05\u20130.61].",
              "Sentence": "Genotypes HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01 Are Not associated with increased and instead are associated with decreased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of the protective HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cThe most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001 and OR = 0.20, p = 0.0003 for models with and without adjustment for the primary HLA-C cluster) (Fig. 2A). The B pocket4, 5 motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99 is characteristic of a cluster of HLA-B B62 supertype alleles: HLA-B*15:(01/12/24/25/27/35) and HLA-B*52:01 (Figure S3 and Table S2), consistent with a previously reported protective HLA-B*15 association with cutaneous NVP reactions observed in an Indian population34.\u201d",
                "\u201cProtective HLA-B alleles HLA-B*15:(01/12/24/25/27/32/35), -B*52:01 0.18 [0.07\u20130.46] \u2026 Asian OR [95% CI] 0.18 [0.05\u20130.61]\u201d",
                "\u201cSimilarly, protection afforded by the protective HLA-B*15:01/-B*52:01 cluster could be explained by dominance of the more highly expressed HLA-B molecules. In the case of protective HLA-B alleles the particular HLA-B-drug\u2014peptide combination may mimic a self-peptide-HLA combination that is tolerated by the host.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*15:01, HLA-B*15:12, HLA-B*15:24, HLA-B*15:25, HLA-B*15:27, HLA-B*15:32, HLA-B*15:35, HLA-B*52:01",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*15:27",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "HLA-B*15:27",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A protective effect for cutaneous nevirapine hypersensitivity was associated with a cluster of HLA-B B62 supertype alleles defined by the B-pocket motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99. Protective alleles were HLA-B*15:01/12/24/25/27/32/35 and HLA-B*52:01. In multivariate models, \"Protective HLA-B alleles\" had OR 0.18 [0.07\u20130.46] overall; Asian OR 0.18 [0.05\u20130.61].",
              "Sentence": "Genotypes HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01 Are Not associated with increased and instead are associated with decreased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of the protective HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cThe most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001 and OR = 0.20, p = 0.0003 for models with and without adjustment for the primary HLA-C cluster) (Fig. 2A). The B pocket4, 5 motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99 is characteristic of a cluster of HLA-B B62 supertype alleles: HLA-B*15:(01/12/24/25/27/35) and HLA-B*52:01 (Figure S3 and Table S2), consistent with a previously reported protective HLA-B*15 association with cutaneous NVP reactions observed in an Indian population34.\u201d",
                "\u201cProtective HLA-B alleles HLA-B*15:(01/12/24/25/27/32/35), -B*52:01 0.18 [0.07\u20130.46] \u2026 Asian OR [95% CI] 0.18 [0.05\u20130.61]\u201d",
                "\u201cSimilarly, protection afforded by the protective HLA-B*15:01/-B*52:01 cluster could be explained by dominance of the more highly expressed HLA-B molecules. In the case of protective HLA-B alleles the particular HLA-B-drug\u2014peptide combination may mimic a self-peptide-HLA combination that is tolerated by the host.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*15:01, HLA-B*15:12, HLA-B*15:24, HLA-B*15:25, HLA-B*15:27, HLA-B*15:32, HLA-B*15:35, HLA-B*52:01",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*15:32",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "HLA-B*15:32",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A protective effect for cutaneous nevirapine hypersensitivity was associated with a cluster of HLA-B B62 supertype alleles defined by the B-pocket motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99. Protective alleles were HLA-B*15:01/12/24/25/27/32/35 and HLA-B*52:01. In multivariate models, \"Protective HLA-B alleles\" had OR 0.18 [0.07\u20130.46] overall; Asian OR 0.18 [0.05\u20130.61].",
              "Sentence": "Genotypes HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01 Are Not associated with increased and instead are associated with decreased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of the protective HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cThe most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001 and OR = 0.20, p = 0.0003 for models with and without adjustment for the primary HLA-C cluster) (Fig. 2A). The B pocket4, 5 motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99 is characteristic of a cluster of HLA-B B62 supertype alleles: HLA-B*15:(01/12/24/25/27/35) and HLA-B*52:01 (Figure S3 and Table S2), consistent with a previously reported protective HLA-B*15 association with cutaneous NVP reactions observed in an Indian population34.\u201d",
                "\u201cProtective HLA-B alleles HLA-B*15:(01/12/24/25/27/32/35), -B*52:01 0.18 [0.07\u20130.46] \u2026 Asian OR [95% CI] 0.18 [0.05\u20130.61]\u201d",
                "\u201cSimilarly, protection afforded by the protective HLA-B*15:01/-B*52:01 cluster could be explained by dominance of the more highly expressed HLA-B molecules. In the case of protective HLA-B alleles the particular HLA-B-drug\u2014peptide combination may mimic a self-peptide-HLA combination that is tolerated by the host.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*15:01, HLA-B*15:12, HLA-B*15:24, HLA-B*15:25, HLA-B*15:27, HLA-B*15:32, HLA-B*15:35, HLA-B*52:01",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*15:35",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "HLA-B*15:35",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A protective effect for cutaneous nevirapine hypersensitivity was associated with a cluster of HLA-B B62 supertype alleles defined by the B-pocket motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99. Protective alleles were HLA-B*15:01/12/24/25/27/32/35 and HLA-B*52:01. In multivariate models, \"Protective HLA-B alleles\" had OR 0.18 [0.07\u20130.46] overall; Asian OR 0.18 [0.05\u20130.61].",
              "Sentence": "Genotypes HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01 Are Not associated with increased and instead are associated with decreased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of the protective HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cThe most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001 and OR = 0.20, p = 0.0003 for models with and without adjustment for the primary HLA-C cluster) (Fig. 2A). The B pocket4, 5 motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99 is characteristic of a cluster of HLA-B B62 supertype alleles: HLA-B*15:(01/12/24/25/27/35) and HLA-B*52:01 (Figure S3 and Table S2), consistent with a previously reported protective HLA-B*15 association with cutaneous NVP reactions observed in an Indian population34.\u201d",
                "\u201cProtective HLA-B alleles HLA-B*15:(01/12/24/25/27/32/35), -B*52:01 0.18 [0.07\u20130.46] \u2026 Asian OR [95% CI] 0.18 [0.05\u20130.61]\u201d",
                "\u201cSimilarly, protection afforded by the protective HLA-B*15:01/-B*52:01 cluster could be explained by dominance of the more highly expressed HLA-B molecules. In the case of protective HLA-B alleles the particular HLA-B-drug\u2014peptide combination may mimic a self-peptide-HLA combination that is tolerated by the host.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*15:01, HLA-B*15:12, HLA-B*15:24, HLA-B*15:25, HLA-B*15:27, HLA-B*15:32, HLA-B*15:35, HLA-B*52:01",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*52:01",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "HLA-B*52:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A protective effect for cutaneous nevirapine hypersensitivity was associated with a cluster of HLA-B B62 supertype alleles defined by the B-pocket motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99. Protective alleles were HLA-B*15:01/12/24/25/27/32/35 and HLA-B*52:01. In multivariate models, \"Protective HLA-B alleles\" had OR 0.18 [0.07\u20130.46] overall; Asian OR 0.18 [0.05\u20130.61].",
              "Sentence": "Genotypes HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01 Are Not associated with increased and instead are associated with decreased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*15:01 + HLA-B*15:12 + HLA-B*15:24 + HLA-B*15:25 + HLA-B*15:27 + HLA-B*15:32 + HLA-B*15:35 + HLA-B*52:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of the protective HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cThe most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001 and OR = 0.20, p = 0.0003 for models with and without adjustment for the primary HLA-C cluster) (Fig. 2A). The B pocket4, 5 motif Tyr7-Tyr9-Ala24-Val34-(Met/Thr)45-Glu63-Ile66-Ser67-Asn70-(Tyr/Phe)99 is characteristic of a cluster of HLA-B B62 supertype alleles: HLA-B*15:(01/12/24/25/27/35) and HLA-B*52:01 (Figure S3 and Table S2), consistent with a previously reported protective HLA-B*15 association with cutaneous NVP reactions observed in an Indian population34.\u201d",
                "\u201cProtective HLA-B alleles HLA-B*15:(01/12/24/25/27/32/35), -B*52:01 0.18 [0.07\u20130.46] \u2026 Asian OR [95% CI] 0.18 [0.05\u20130.61]\u201d",
                "\u201cSimilarly, protection afforded by the protective HLA-B*15:01/-B*52:01 cluster could be explained by dominance of the more highly expressed HLA-B molecules. In the case of protective HLA-B alleles the particular HLA-B-drug\u2014peptide combination may mimic a self-peptide-HLA combination that is tolerated by the host.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*15:01, HLA-B*15:12, HLA-B*15:24, HLA-B*15:25, HLA-B*15:27, HLA-B*15:32, HLA-B*15:35, HLA-B*52:01",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*51:01",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*51:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models. The HLA-B*38/*39 group (including B*39:10) was characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models (Fig. 3, Table 2).",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*51:01, HLA-B*51:02, HLA-B*54:01, HLA-B*55:01, HLA-B*55:02, HLA-B*56:01, HLA-B*56:04, HLA-B*67:01, HLA-B*78:01, HLA-B*39:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*51:02",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*51:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models. The HLA-B*38/*39 group (including B*39:10) was characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models (Fig. 3, Table 2).",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*51:01, HLA-B*51:02, HLA-B*54:01, HLA-B*55:01, HLA-B*55:02, HLA-B*56:01, HLA-B*56:04, HLA-B*67:01, HLA-B*78:01, HLA-B*39:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*54:01",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*54:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models. The HLA-B*38/*39 group (including B*39:10) was characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models (Fig. 3, Table 2).",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*51:01, HLA-B*51:02, HLA-B*54:01, HLA-B*55:01, HLA-B*55:02, HLA-B*56:01, HLA-B*56:04, HLA-B*67:01, HLA-B*78:01, HLA-B*39:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*55:01",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*55:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models. The HLA-B*38/*39 group (including B*39:10) was characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models (Fig. 3, Table 2).",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*51:01, HLA-B*51:02, HLA-B*54:01, HLA-B*55:01, HLA-B*55:02, HLA-B*56:01, HLA-B*56:04, HLA-B*67:01, HLA-B*78:01, HLA-B*39:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*55:02",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*55:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models. The HLA-B*38/*39 group (including B*39:10) was characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models (Fig. 3, Table 2).",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*51:01, HLA-B*51:02, HLA-B*54:01, HLA-B*55:01, HLA-B*55:02, HLA-B*56:01, HLA-B*56:04, HLA-B*67:01, HLA-B*78:01, HLA-B*39:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*56:01",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*56:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models. The HLA-B*38/*39 group (including B*39:10) was characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models (Fig. 3, Table 2).",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*51:01, HLA-B*51:02, HLA-B*54:01, HLA-B*55:01, HLA-B*55:02, HLA-B*56:01, HLA-B*56:04, HLA-B*67:01, HLA-B*78:01, HLA-B*39:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*56:04",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*56:04",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models. The HLA-B*38/*39 group (including B*39:10) was characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models (Fig. 3, Table 2).",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*51:01, HLA-B*51:02, HLA-B*54:01, HLA-B*55:01, HLA-B*55:02, HLA-B*56:01, HLA-B*56:04, HLA-B*67:01, HLA-B*78:01, HLA-B*39:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*67:01",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*67:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models. The HLA-B*38/*39 group (including B*39:10) was characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models (Fig. 3, Table 2).",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*51:01, HLA-B*51:02, HLA-B*54:01, HLA-B*55:01, HLA-B*55:02, HLA-B*56:01, HLA-B*56:04, HLA-B*67:01, HLA-B*78:01, HLA-B*39:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*78:01",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*78:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models. The HLA-B*38/*39 group (including B*39:10) was characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models (Fig. 3, Table 2).",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*51:01, HLA-B*51:02, HLA-B*54:01, HLA-B*55:01, HLA-B*55:02, HLA-B*56:01, HLA-B*56:04, HLA-B*67:01, HLA-B*78:01, HLA-B*39:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*39:10",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "HLA-B*39:10",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models. The HLA-B*38/*39 group (including B*39:10) was characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*51:01 + HLA-B*51:02 + HLA-B*54:01 + HLA-B*55:01 + HLA-B*55:02 + HLA-B*56:01 + HLA-B*56:04 + HLA-B*67:01 + HLA-B*78:01 + HLA-B*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk B07 supertype alleles (HLA-B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) showed an overall increased risk of cutaneous nevirapine hypersensitivity with OR 2.32 [1.42\u20133.79] in multivariate models (Fig. 3, Table 2).",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*51:01, HLA-B*51:02, HLA-B*54:01, HLA-B*55:01, HLA-B*55:02, HLA-B*56:01, HLA-B*56:04, HLA-B*67:01, HLA-B*78:01, HLA-B*39:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*13:02",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "HLA-B*13:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "\"Risk non-B07 HLA-B alleles\" HLA-B*13:02, B*38:(01/02), B*39:(01/05/06/09), and B*51:07 had OR 1.76 [1.02\u20133.02] for cutaneous nevirapine hypersensitivity in multivariate models. These risk alleles include B27-supertype B*38 and B*39 alleles characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk non-B07 HLA-B alleles HLA-B*13:02, B*38:(01/02), -B*39:(01/05/06/09), B*51:07 | 1.76 [1.02\u20133.02] | 1.87 [0.76\u20134.57] | 1.50 [0.72\u20133.12] | 5.54 [0.30\u2013101.20]",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27.",
                "While there was no single common HLA binding pocket motif that characterised the HLA-B B07 and B27 supertype risk alleles, the HLA-B*38/-B*39 group was characterised by the E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156 and the B07 HLA-B risk alleles by the sequence Trp95-Thr97-Asn114-(Phe/Leu/Tyr)116-(Val/Glu)152-Leu156 (Table S3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*13:02, HLA-B*38:01, HLA-B*38:02, HLA-B*39:01, HLA-B*39:05, HLA-B*39:06, HLA-B*39:09, HLA-B*51:07",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*38:01",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "HLA-B*38:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "\"Risk non-B07 HLA-B alleles\" HLA-B*13:02, B*38:(01/02), B*39:(01/05/06/09), and B*51:07 had OR 1.76 [1.02\u20133.02] for cutaneous nevirapine hypersensitivity in multivariate models. These risk alleles include B27-supertype B*38 and B*39 alleles characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk non-B07 HLA-B alleles HLA-B*13:02, B*38:(01/02), -B*39:(01/05/06/09), B*51:07 | 1.76 [1.02\u20133.02] | 1.87 [0.76\u20134.57] | 1.50 [0.72\u20133.12] | 5.54 [0.30\u2013101.20]",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27.",
                "While there was no single common HLA binding pocket motif that characterised the HLA-B B07 and B27 supertype risk alleles, the HLA-B*38/-B*39 group was characterised by the E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156 and the B07 HLA-B risk alleles by the sequence Trp95-Thr97-Asn114-(Phe/Leu/Tyr)116-(Val/Glu)152-Leu156 (Table S3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*13:02, HLA-B*38:01, HLA-B*38:02, HLA-B*39:01, HLA-B*39:05, HLA-B*39:06, HLA-B*39:09, HLA-B*51:07",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*38:02",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "HLA-B*38:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "\"Risk non-B07 HLA-B alleles\" HLA-B*13:02, B*38:(01/02), B*39:(01/05/06/09), and B*51:07 had OR 1.76 [1.02\u20133.02] for cutaneous nevirapine hypersensitivity in multivariate models. These risk alleles include B27-supertype B*38 and B*39 alleles characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk non-B07 HLA-B alleles HLA-B*13:02, B*38:(01/02), -B*39:(01/05/06/09), B*51:07 | 1.76 [1.02\u20133.02] | 1.87 [0.76\u20134.57] | 1.50 [0.72\u20133.12] | 5.54 [0.30\u2013101.20]",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27.",
                "While there was no single common HLA binding pocket motif that characterised the HLA-B B07 and B27 supertype risk alleles, the HLA-B*38/-B*39 group was characterised by the E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156 and the B07 HLA-B risk alleles by the sequence Trp95-Thr97-Asn114-(Phe/Leu/Tyr)116-(Val/Glu)152-Leu156 (Table S3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*13:02, HLA-B*38:01, HLA-B*38:02, HLA-B*39:01, HLA-B*39:05, HLA-B*39:06, HLA-B*39:09, HLA-B*51:07",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*39:01",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "HLA-B*39:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "\"Risk non-B07 HLA-B alleles\" HLA-B*13:02, B*38:(01/02), B*39:(01/05/06/09), and B*51:07 had OR 1.76 [1.02\u20133.02] for cutaneous nevirapine hypersensitivity in multivariate models. These risk alleles include B27-supertype B*38 and B*39 alleles characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk non-B07 HLA-B alleles HLA-B*13:02, B*38:(01/02), -B*39:(01/05/06/09), B*51:07 | 1.76 [1.02\u20133.02] | 1.87 [0.76\u20134.57] | 1.50 [0.72\u20133.12] | 5.54 [0.30\u2013101.20]",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27.",
                "While there was no single common HLA binding pocket motif that characterised the HLA-B B07 and B27 supertype risk alleles, the HLA-B*38/-B*39 group was characterised by the E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156 and the B07 HLA-B risk alleles by the sequence Trp95-Thr97-Asn114-(Phe/Leu/Tyr)116-(Val/Glu)152-Leu156 (Table S3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*13:02, HLA-B*38:01, HLA-B*38:02, HLA-B*39:01, HLA-B*39:05, HLA-B*39:06, HLA-B*39:09, HLA-B*51:07",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*39:05",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "HLA-B*39:05",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "\"Risk non-B07 HLA-B alleles\" HLA-B*13:02, B*38:(01/02), B*39:(01/05/06/09), and B*51:07 had OR 1.76 [1.02\u20133.02] for cutaneous nevirapine hypersensitivity in multivariate models. These risk alleles include B27-supertype B*38 and B*39 alleles characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk non-B07 HLA-B alleles HLA-B*13:02, B*38:(01/02), -B*39:(01/05/06/09), B*51:07 | 1.76 [1.02\u20133.02] | 1.87 [0.76\u20134.57] | 1.50 [0.72\u20133.12] | 5.54 [0.30\u2013101.20]",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27.",
                "While there was no single common HLA binding pocket motif that characterised the HLA-B B07 and B27 supertype risk alleles, the HLA-B*38/-B*39 group was characterised by the E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156 and the B07 HLA-B risk alleles by the sequence Trp95-Thr97-Asn114-(Phe/Leu/Tyr)116-(Val/Glu)152-Leu156 (Table S3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*13:02, HLA-B*38:01, HLA-B*38:02, HLA-B*39:01, HLA-B*39:05, HLA-B*39:06, HLA-B*39:09, HLA-B*51:07",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*39:06",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "HLA-B*39:06",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "\"Risk non-B07 HLA-B alleles\" HLA-B*13:02, B*38:(01/02), B*39:(01/05/06/09), and B*51:07 had OR 1.76 [1.02\u20133.02] for cutaneous nevirapine hypersensitivity in multivariate models. These risk alleles include B27-supertype B*38 and B*39 alleles characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk non-B07 HLA-B alleles HLA-B*13:02, B*38:(01/02), -B*39:(01/05/06/09), B*51:07 | 1.76 [1.02\u20133.02] | 1.87 [0.76\u20134.57] | 1.50 [0.72\u20133.12] | 5.54 [0.30\u2013101.20]",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27.",
                "While there was no single common HLA binding pocket motif that characterised the HLA-B B07 and B27 supertype risk alleles, the HLA-B*38/-B*39 group was characterised by the E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156 and the B07 HLA-B risk alleles by the sequence Trp95-Thr97-Asn114-(Phe/Leu/Tyr)116-(Val/Glu)152-Leu156 (Table S3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*13:02, HLA-B*38:01, HLA-B*38:02, HLA-B*39:01, HLA-B*39:05, HLA-B*39:06, HLA-B*39:09, HLA-B*51:07",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*39:09",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "HLA-B*39:09",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "\"Risk non-B07 HLA-B alleles\" HLA-B*13:02, B*38:(01/02), B*39:(01/05/06/09), and B*51:07 had OR 1.76 [1.02\u20133.02] for cutaneous nevirapine hypersensitivity in multivariate models. These risk alleles include B27-supertype B*38 and B*39 alleles characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk non-B07 HLA-B alleles HLA-B*13:02, B*38:(01/02), -B*39:(01/05/06/09), B*51:07 | 1.76 [1.02\u20133.02] | 1.87 [0.76\u20134.57] | 1.50 [0.72\u20133.12] | 5.54 [0.30\u2013101.20]",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27.",
                "While there was no single common HLA binding pocket motif that characterised the HLA-B B07 and B27 supertype risk alleles, the HLA-B*38/-B*39 group was characterised by the E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156 and the B07 HLA-B risk alleles by the sequence Trp95-Thr97-Asn114-(Phe/Leu/Tyr)116-(Val/Glu)152-Leu156 (Table S3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*13:02, HLA-B*38:01, HLA-B*38:02, HLA-B*39:01, HLA-B*39:05, HLA-B*39:06, HLA-B*39:09, HLA-B*51:07",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-B*51:07",
            "gene": "HLA-B",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "HLA-B*51:07",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "\"Risk non-B07 HLA-B alleles\" HLA-B*13:02, B*38:(01/02), B*39:(01/05/06/09), and B*51:07 had OR 1.76 [1.02\u20133.02] for cutaneous nevirapine hypersensitivity in multivariate models. These risk alleles include B27-supertype B*38 and B*39 alleles characterized by an E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156.",
              "Sentence": "Genotypes HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-B alleles.",
              "Alleles": "HLA-B*13:02 + HLA-B*38:01 + HLA-B*38:02 + HLA-B*39:01 + HLA-B*39:05 + HLA-B*39:06 + HLA-B*39:09 + HLA-B*51:07",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-B alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Risk non-B07 HLA-B alleles HLA-B*13:02, B*38:(01/02), -B*39:(01/05/06/09), B*51:07 | 1.76 [1.02\u20133.02] | 1.87 [0.76\u20134.57] | 1.50 [0.72\u20133.12] | 5.54 [0.30\u2013101.20]",
                "Other secondary HLA-B risk alleles were identified by analysis of supertypes in combination with MHCcluster designated peptide binding specificities after adjusting for the effect of the HLA-C*04:01 risk allele group (Figure S3, Table 1). These included HLA-B*51/-B*54/-B*55/-B*56 from the supertype B07 and HLA-B*38/-B*39 from supertype B27.",
                "While there was no single common HLA binding pocket motif that characterised the HLA-B B07 and B27 supertype risk alleles, the HLA-B*38/-B*39 group was characterised by the E/F pocket sequence Leu95-Arg97-Asn114-(Phe/Lys)116-Val152-Leu156 and the B07 HLA-B risk alleles by the sequence Trp95-Thr97-Asn114-(Phe/Leu/Tyr)116-(Val/Glu)152-Leu156 (Table S3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-B*13:02, HLA-B*38:01, HLA-B*38:02, HLA-B*39:01, HLA-B*39:05, HLA-B*39:06, HLA-B*39:09, HLA-B*51:07",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-DRB1*01:01",
            "gene": "HLA-DRB1",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "HLA-DRB1*01:01",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A class II risk cluster of HLA-DRB1*01:(01/02/03) and HLA-DRB1*04:(04/05/08/10) sharing a P4 pocket sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 showed a secondary association with cutaneous nevirapine hypersensitivity. In multivariate models, \"Risk HLA-DRB1 alleles\" had OR 2.00 [1.23\u20133.24] overall; Asian OR 3.23 [1.40\u20137.43]. HLA-DRB1*01:01 and *01:02 have previously been associated with nevirapine hepatic hypersensitivity.",
              "Sentence": "Genotypes HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-DRB1 alleles.",
              "Alleles": "HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-DRB1 alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "From MHCcluster and binding groove analyses of the HLA-DRB1 alleles within the cohort we identified a cluster including both supertype HLA-DR1 and -DR4 alleles (HLA-*DRB1*01:*(*01*/02/03) and *-DRB1**04*:*(*04*/05/08/10), respectively) that exhibited a secondary association with cutaneous NVP HSR (Fig. [2A](#Fig2)).",
                "The identified risk alleles for cutaneous NVP HSR share the sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 over residues forming the P4 pocket (Table [S4](#MOESM1)).",
                "Risk HLA-DRB1 alleles HLA-DRB1*01:(01/02/03), -DRB1*04:(04/05/08/10) | 2.00 [1.23\u20133.24] | 1.34 [0.68\u20132.64] | 3.23 [1.40\u20137.43] | 4.77 [0.95\u201324.04]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-DRB1*01:01, HLA-DRB1*01:02, HLA-DRB1*01:03, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:08, HLA-DRB1*04:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-DRB1*01:02",
            "gene": "HLA-DRB1",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "HLA-DRB1*01:02",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A class II risk cluster of HLA-DRB1*01:(01/02/03) and HLA-DRB1*04:(04/05/08/10) sharing a P4 pocket sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 showed a secondary association with cutaneous nevirapine hypersensitivity. In multivariate models, \"Risk HLA-DRB1 alleles\" had OR 2.00 [1.23\u20133.24] overall; Asian OR 3.23 [1.40\u20137.43]. HLA-DRB1*01:01 and *01:02 have previously been associated with nevirapine hepatic hypersensitivity.",
              "Sentence": "Genotypes HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-DRB1 alleles.",
              "Alleles": "HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-DRB1 alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "From MHCcluster and binding groove analyses of the HLA-DRB1 alleles within the cohort we identified a cluster including both supertype HLA-DR1 and -DR4 alleles (HLA-*DRB1*01:*(*01*/02/03) and *-DRB1**04*:*(*04*/05/08/10), respectively) that exhibited a secondary association with cutaneous NVP HSR (Fig. [2A](#Fig2)).",
                "The identified risk alleles for cutaneous NVP HSR share the sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 over residues forming the P4 pocket (Table [S4](#MOESM1)).",
                "Risk HLA-DRB1 alleles HLA-DRB1*01:(01/02/03), -DRB1*04:(04/05/08/10) | 2.00 [1.23\u20133.24] | 1.34 [0.68\u20132.64] | 3.23 [1.40\u20137.43] | 4.77 [0.95\u201324.04]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-DRB1*01:01, HLA-DRB1*01:02, HLA-DRB1*01:03, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:08, HLA-DRB1*04:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-DRB1*01:03",
            "gene": "HLA-DRB1",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "HLA-DRB1*01:03",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A class II risk cluster of HLA-DRB1*01:(01/02/03) and HLA-DRB1*04:(04/05/08/10) sharing a P4 pocket sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 showed a secondary association with cutaneous nevirapine hypersensitivity. In multivariate models, \"Risk HLA-DRB1 alleles\" had OR 2.00 [1.23\u20133.24] overall; Asian OR 3.23 [1.40\u20137.43]. HLA-DRB1*01:01 and *01:02 have previously been associated with nevirapine hepatic hypersensitivity.",
              "Sentence": "Genotypes HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-DRB1 alleles.",
              "Alleles": "HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-DRB1 alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "From MHCcluster and binding groove analyses of the HLA-DRB1 alleles within the cohort we identified a cluster including both supertype HLA-DR1 and -DR4 alleles (HLA-*DRB1*01:*(*01*/02/03) and *-DRB1**04*:*(*04*/05/08/10), respectively) that exhibited a secondary association with cutaneous NVP HSR (Fig. [2A](#Fig2)).",
                "The identified risk alleles for cutaneous NVP HSR share the sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 over residues forming the P4 pocket (Table [S4](#MOESM1)).",
                "Risk HLA-DRB1 alleles HLA-DRB1*01:(01/02/03), -DRB1*04:(04/05/08/10) | 2.00 [1.23\u20133.24] | 1.34 [0.68\u20132.64] | 3.23 [1.40\u20137.43] | 4.77 [0.95\u201324.04]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-DRB1*01:01, HLA-DRB1*01:02, HLA-DRB1*01:03, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:08, HLA-DRB1*04:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-DRB1*04:04",
            "gene": "HLA-DRB1",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "HLA-DRB1*04:04",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A class II risk cluster of HLA-DRB1*01:(01/02/03) and HLA-DRB1*04:(04/05/08/10) sharing a P4 pocket sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 showed a secondary association with cutaneous nevirapine hypersensitivity. In multivariate models, \"Risk HLA-DRB1 alleles\" had OR 2.00 [1.23\u20133.24] overall; Asian OR 3.23 [1.40\u20137.43]. HLA-DRB1*01:01 and *01:02 have previously been associated with nevirapine hepatic hypersensitivity.",
              "Sentence": "Genotypes HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-DRB1 alleles.",
              "Alleles": "HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-DRB1 alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "From MHCcluster and binding groove analyses of the HLA-DRB1 alleles within the cohort we identified a cluster including both supertype HLA-DR1 and -DR4 alleles (HLA-*DRB1*01:*(*01*/02/03) and *-DRB1**04*:*(*04*/05/08/10), respectively) that exhibited a secondary association with cutaneous NVP HSR (Fig. [2A](#Fig2)).",
                "The identified risk alleles for cutaneous NVP HSR share the sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 over residues forming the P4 pocket (Table [S4](#MOESM1)).",
                "Risk HLA-DRB1 alleles HLA-DRB1*01:(01/02/03), -DRB1*04:(04/05/08/10) | 2.00 [1.23\u20133.24] | 1.34 [0.68\u20132.64] | 3.23 [1.40\u20137.43] | 4.77 [0.95\u201324.04]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-DRB1*01:01, HLA-DRB1*01:02, HLA-DRB1*01:03, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:08, HLA-DRB1*04:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-DRB1*04:05",
            "gene": "HLA-DRB1",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "HLA-DRB1*04:05",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A class II risk cluster of HLA-DRB1*01:(01/02/03) and HLA-DRB1*04:(04/05/08/10) sharing a P4 pocket sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 showed a secondary association with cutaneous nevirapine hypersensitivity. In multivariate models, \"Risk HLA-DRB1 alleles\" had OR 2.00 [1.23\u20133.24] overall; Asian OR 3.23 [1.40\u20137.43]. HLA-DRB1*01:01 and *01:02 have previously been associated with nevirapine hepatic hypersensitivity.",
              "Sentence": "Genotypes HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-DRB1 alleles.",
              "Alleles": "HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-DRB1 alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "From MHCcluster and binding groove analyses of the HLA-DRB1 alleles within the cohort we identified a cluster including both supertype HLA-DR1 and -DR4 alleles (HLA-*DRB1*01:*(*01*/02/03) and *-DRB1**04*:*(*04*/05/08/10), respectively) that exhibited a secondary association with cutaneous NVP HSR (Fig. [2A](#Fig2)).",
                "The identified risk alleles for cutaneous NVP HSR share the sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 over residues forming the P4 pocket (Table [S4](#MOESM1)).",
                "Risk HLA-DRB1 alleles HLA-DRB1*01:(01/02/03), -DRB1*04:(04/05/08/10) | 2.00 [1.23\u20133.24] | 1.34 [0.68\u20132.64] | 3.23 [1.40\u20137.43] | 4.77 [0.95\u201324.04]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-DRB1*01:01, HLA-DRB1*01:02, HLA-DRB1*01:03, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:08, HLA-DRB1*04:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-DRB1*04:08",
            "gene": "HLA-DRB1",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "HLA-DRB1*04:08",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A class II risk cluster of HLA-DRB1*01:(01/02/03) and HLA-DRB1*04:(04/05/08/10) sharing a P4 pocket sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 showed a secondary association with cutaneous nevirapine hypersensitivity. In multivariate models, \"Risk HLA-DRB1 alleles\" had OR 2.00 [1.23\u20133.24] overall; Asian OR 3.23 [1.40\u20137.43]. HLA-DRB1*01:01 and *01:02 have previously been associated with nevirapine hepatic hypersensitivity.",
              "Sentence": "Genotypes HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-DRB1 alleles.",
              "Alleles": "HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-DRB1 alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "From MHCcluster and binding groove analyses of the HLA-DRB1 alleles within the cohort we identified a cluster including both supertype HLA-DR1 and -DR4 alleles (HLA-*DRB1*01:*(*01*/02/03) and *-DRB1**04*:*(*04*/05/08/10), respectively) that exhibited a secondary association with cutaneous NVP HSR (Fig. [2A](#Fig2)).",
                "The identified risk alleles for cutaneous NVP HSR share the sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 over residues forming the P4 pocket (Table [S4](#MOESM1)).",
                "Risk HLA-DRB1 alleles HLA-DRB1*01:(01/02/03), -DRB1*04:(04/05/08/10) | 2.00 [1.23\u20133.24] | 1.34 [0.68\u20132.64] | 3.23 [1.40\u20137.43] | 4.77 [0.95\u201324.04]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-DRB1*01:01, HLA-DRB1*01:02, HLA-DRB1*01:03, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:08, HLA-DRB1*04:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HLA-DRB1*04:10",
            "gene": "HLA-DRB1",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "HLA-DRB1*04:10",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "A class II risk cluster of HLA-DRB1*01:(01/02/03) and HLA-DRB1*04:(04/05/08/10) sharing a P4 pocket sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 showed a secondary association with cutaneous nevirapine hypersensitivity. In multivariate models, \"Risk HLA-DRB1 alleles\" had OR 2.00 [1.23\u20133.24] overall; Asian OR 3.23 [1.40\u20137.43]. HLA-DRB1*01:01 and *01:02 have previously been associated with nevirapine hepatic hypersensitivity.",
              "Sentence": "Genotypes HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10 Are Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to non-carriers of these HLA-DRB1 alleles.",
              "Alleles": "HLA-DRB1*01:01 + HLA-DRB1*01:02 + HLA-DRB1*01:03 + HLA-DRB1*04:04 + HLA-DRB1*04:05 + HLA-DRB1*04:08 + HLA-DRB1*04:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "non-carriers of these HLA-DRB1 alleles",
              "Comparison Metabolizer types": null,
              "Citations": [
                "From MHCcluster and binding groove analyses of the HLA-DRB1 alleles within the cohort we identified a cluster including both supertype HLA-DR1 and -DR4 alleles (HLA-*DRB1*01:*(*01*/02/03) and *-DRB1**04*:*(*04*/05/08/10), respectively) that exhibited a secondary association with cutaneous NVP HSR (Fig. [2A](#Fig2)).",
                "The identified risk alleles for cutaneous NVP HSR share the sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 over residues forming the P4 pocket (Table [S4](#MOESM1)).",
                "Risk HLA-DRB1 alleles HLA-DRB1*01:(01/02/03), -DRB1*04:(04/05/08/10) | 2.00 [1.23\u20133.24] | 1.34 [0.68\u20132.64] | 3.23 [1.40\u20137.43] | 4.77 [0.95\u201324.04]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HLA-DRB1*01:01, HLA-DRB1*01:02, HLA-DRB1*01:03, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:08, HLA-DRB1*04:10",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "CYP2B6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slow CYP2B6 metabolizer genotype, defined by variants 516 G\u2192T and 983 T\u2192C in prior work on this cohort, was associated with increased risk of cutaneous nevirapine hypersensitivity. In multivariate models, \"Slow CYP2B6 metabolizer\" had OR 2.07 [1.12\u20133.82] overall; Caucasian OR 3.19 [1.04\u20139.78]. These genotypes correlate with increased plasma levels of nevirapine and increased risk for class I HLA-restricted cutaneous NVP HSR.",
              "Sentence": "CYP2B6 slow metabolizer Is Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to CYP2B6 normal metabolizer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": "slow metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2B6 normal metabolizer",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cMultivariate modelling was used to examine overall risk for cutaneous NVP HSR associated with the identified predisposing and protective clusters in both whole-cohort and ancestry-specific analyses. The cluster effects remain strong when the models additionally account for the independent impact of NVP metabolism as conferred by *CYP2B6* genotype, noted previously in this cohort^21^ (Table [2](#Tab2)).\u201d",
                "\u201cTable 2 Caption: Multivariate logistic regression model of predisposition to cutaneous NVP HSR, according to ancestry.\n\u2026\n| Slow CYP2B6 metabolizer | 2.07 [1.12\u20133.82] | 3.19 [1.04\u20139.78] | 1.66 [0.64\u20134.32] | 1.81 [0.45\u20137.33] |\u201d",
                "\u201cFor example, slow metabolizer genotypes for *CYP2B6* (516 G \u2192 T and 983 T \u2192 C) have previously been shown to correlate with both increased plasma levels of NVP and increased risk for class I HLA restricted cutaneous NVP HSR^54\u201356^.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6 slow metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "slow",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "slow",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slow CYP2B6 metabolizer genotype, defined by variants 516 G\u2192T and 983 T\u2192C in prior work on this cohort, was associated with increased risk of cutaneous nevirapine hypersensitivity. In multivariate models, \"Slow CYP2B6 metabolizer\" had OR 2.07 [1.12\u20133.82] overall; Caucasian OR 3.19 [1.04\u20139.78]. These genotypes correlate with increased plasma levels of nevirapine and increased risk for class I HLA-restricted cutaneous NVP HSR.",
              "Sentence": "CYP2B6 slow metabolizer Is Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to CYP2B6 normal metabolizer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": "slow metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2B6 normal metabolizer",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cMultivariate modelling was used to examine overall risk for cutaneous NVP HSR associated with the identified predisposing and protective clusters in both whole-cohort and ancestry-specific analyses. The cluster effects remain strong when the models additionally account for the independent impact of NVP metabolism as conferred by *CYP2B6* genotype, noted previously in this cohort^21^ (Table [2](#Tab2)).\u201d",
                "\u201cTable 2 Caption: Multivariate logistic regression model of predisposition to cutaneous NVP HSR, according to ancestry.\n\u2026\n| Slow CYP2B6 metabolizer | 2.07 [1.12\u20133.82] | 3.19 [1.04\u20139.78] | 1.66 [0.64\u20134.32] | 1.81 [0.45\u20137.33] |\u201d",
                "\u201cFor example, slow metabolizer genotypes for *CYP2B6* (516 G \u2192 T and 983 T \u2192 C) have previously been shown to correlate with both increased plasma levels of NVP and increased risk for class I HLA restricted cutaneous NVP HSR^54\u201356^.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6 slow metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slow CYP2B6 metabolizer genotype, defined by variants 516 G\u2192T and 983 T\u2192C in prior work on this cohort, was associated with increased risk of cutaneous nevirapine hypersensitivity. In multivariate models, \"Slow CYP2B6 metabolizer\" had OR 2.07 [1.12\u20133.82] overall; Caucasian OR 3.19 [1.04\u20139.78]. These genotypes correlate with increased plasma levels of nevirapine and increased risk for class I HLA-restricted cutaneous NVP HSR.",
              "Sentence": "CYP2B6 slow metabolizer Is Associated with increased risk of cutaneous hypersensitivity reactions to nevirapine in patients with HIV infectious disease as compared to CYP2B6 normal metabolizer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": "slow metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of cutaneous hypersensitivity reactions to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2B6 normal metabolizer",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cMultivariate modelling was used to examine overall risk for cutaneous NVP HSR associated with the identified predisposing and protective clusters in both whole-cohort and ancestry-specific analyses. The cluster effects remain strong when the models additionally account for the independent impact of NVP metabolism as conferred by *CYP2B6* genotype, noted previously in this cohort^21^ (Table [2](#Tab2)).\u201d",
                "\u201cTable 2 Caption: Multivariate logistic regression model of predisposition to cutaneous NVP HSR, according to ancestry.\n\u2026\n| Slow CYP2B6 metabolizer | 2.07 [1.12\u20133.82] | 3.19 [1.04\u20139.78] | 1.66 [0.64\u20134.32] | 1.81 [0.45\u20137.33] |\u201d",
                "\u201cFor example, slow metabolizer genotypes for *CYP2B6* (516 G \u2192 T and 983 T \u2192 C) have previously been shown to correlate with both increased plasma levels of NVP and increased risk for class I HLA restricted cutaneous NVP HSR^54\u201356^.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6 slow metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.25417981568232983,
      "total_samples": 43,
      "ground_truth_annotations": {
        "count": 43,
        "matched_count": 13,
        "unmatched_count": 30,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.8929244160652161,
            "annotation": {
              "Variant/Haplotypes": "HLA-B*15:32",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*15:32",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:32",
                "prediction": "HLA-B*15:32",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*15:32",
                "prediction": "*15:32",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-B*15:32 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8929244160652161,
            "annotation": {
              "Variant/Haplotypes": "HLA-B*15:35",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*15:35",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:35",
                "prediction": "HLA-B*15:35",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*15:35",
                "prediction": "*15:35",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-B*15:35 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8929244160652161,
            "annotation": {
              "Variant/Haplotypes": "HLA-B*15:12",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*15:12",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:12",
                "prediction": "HLA-B*15:12",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*15:12",
                "prediction": "*15:12",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-B*15:12 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8929244160652161,
            "annotation": {
              "Variant/Haplotypes": "HLA-B*15:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*15:01",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:01",
                "prediction": "HLA-B*15:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*15:01",
                "prediction": "*15:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-B*15:01 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8929244160652161,
            "annotation": {
              "Variant/Haplotypes": "HLA-B*15:27",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*15:27",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:27",
                "prediction": "HLA-B*15:27",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*15:27",
                "prediction": "*15:27",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-B*15:27 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8929244160652161,
            "annotation": {
              "Variant/Haplotypes": "HLA-B*15:25",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*15:25",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:25",
                "prediction": "HLA-B*15:25",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*15:25",
                "prediction": "*15:25",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-B*15:25 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8929244160652161,
            "annotation": {
              "Variant/Haplotypes": "HLA-B*15:24",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*15:24",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:24",
                "prediction": "HLA-B*15:24",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*15:24",
                "prediction": "*15:24",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-B*15:24 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8927462518215179,
            "annotation": {
              "Variant/Haplotypes": "HLA-B*52:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*52:01",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*52:01",
                "prediction": "HLA-B*52:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*52:01",
                "prediction": "*52:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9274625182151794,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-B*52:01 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.792924416065216,
            "annotation": {
              "Variant/Haplotypes": "HLA-C*05:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*05:01",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*05:01",
                "prediction": "HLA-C*05:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "HLA-C",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*05:01",
                "prediction": "*05:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-C*05:01 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.792924416065216,
            "annotation": {
              "Variant/Haplotypes": "HLA-B*35:05",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*35:05",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*35:05",
                "prediction": "HLA-B*35:05",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*35:05",
                "prediction": "*35:05",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "other HLA-B alleles including non-HLA-B*35:05",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.792924416065216,
            "annotation": {
              "Variant/Haplotypes": "HLA-DRB1*01:01",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*01:01",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DRB1*01:01",
                "prediction": "HLA-DRB1*01:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-DRB1",
                "prediction": "HLA-DRB1",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*01:01",
                "prediction": "*01:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-DRB1*01:01 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.792924416065216,
            "annotation": {
              "Variant/Haplotypes": "HLA-C*04:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*04:01",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*04:01",
                "prediction": "HLA-C*04:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "HLA-C",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*04:01",
                "prediction": "*04:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-C*04:01 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.792924416065216,
            "annotation": {
              "Variant/Haplotypes": "HLA-C*18:01",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*18:01",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*18:01",
                "prediction": "HLA-C*18:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "HLA-C",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*18:01",
                "prediction": "*18:01",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous hypersensitivity rash",
                "score": 0.9292441606521606,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-HLA-C*18:01 carriers",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926055,
              "Variant/Haplotypes": "HLA-B*67:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *67:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*67:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926055"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926065,
              "Variant/Haplotypes": "HLA-B*78:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *78:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*78:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926065"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448925992,
              "Variant/Haplotypes": "HLA-B*51:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *51:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*51:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925992"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926045,
              "Variant/Haplotypes": "HLA-B*56:06",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *56:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*56:06",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926045"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926109,
              "Variant/Haplotypes": "HLA-B*39:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *39:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*39:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926109"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448925913,
              "Variant/Haplotypes": "HLA-C*05:09",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
              "Sentence": "HLA-C *05:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*05:09",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925913"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448925982,
              "Variant/Haplotypes": "HLA-B*51:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *51:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*51:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925982"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926299,
              "Variant/Haplotypes": "HLA-DRB1*08:01",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
              "Sentence": "HLA-DRB1 *08:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*08:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926299"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448925972,
              "Variant/Haplotypes": "HLA-B*39:10",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *39:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*39:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925972"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926099,
              "Variant/Haplotypes": "HLA-B*38:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *38:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*38:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926099"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926089,
              "Variant/Haplotypes": "HLA-B*38:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *38:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*38:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926089"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926289,
              "Variant/Haplotypes": "HLA-DRB1*04:04",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
              "Sentence": "HLA-DRB1 *04:04 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*04:04",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926289"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926035,
              "Variant/Haplotypes": "HLA-B*56:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *56:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*56:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926035"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926269,
              "Variant/Haplotypes": "HLA-DRB1*01:02",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
              "Sentence": "HLA-DRB1 *01:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*01:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926269"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926139,
              "Variant/Haplotypes": "HLA-B*39:09",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *39:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*39:09",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926139"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448998275,
              "Variant/Haplotypes": "HLA-B*35:10",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-B*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *35:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*35:10",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448998275"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448925883,
              "Variant/Haplotypes": "HLA-C*04:06",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
              "Sentence": "HLA-C *04:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*04:06",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925883"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926149,
              "Variant/Haplotypes": "HLA-B*57:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *57:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*57:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926149"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448925893,
              "Variant/Haplotypes": "HLA-C*04:07",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
              "Sentence": "HLA-C *04:07 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*04:07",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925893"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926022,
              "Variant/Haplotypes": "HLA-B*55:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *55:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*55:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926022"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926279,
              "Variant/Haplotypes": "HLA-DRB1*01:03",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
              "Sentence": "HLA-DRB1 *01:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*01:03",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926279"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926012,
              "Variant/Haplotypes": "HLA-B*55:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *55:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*55:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926012"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926075,
              "Variant/Haplotypes": "HLA-B*13:02",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *13:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*13:02",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926075"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926129,
              "Variant/Haplotypes": "HLA-B*39:06",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *39:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*39:06",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926129"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448925873,
              "Variant/Haplotypes": "HLA-C*04:03",
              "Gene": "HLA-C",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
              "Sentence": "HLA-C *04:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*04:03",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448925873"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926002,
              "Variant/Haplotypes": "HLA-B*54:01",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
              "Sentence": "HLA-B *54:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*54:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926002"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926309,
              "Variant/Haplotypes": "HLA-DRB1*10:01",
              "Gene": "HLA-DRB1",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
              "Sentence": "HLA-DRB1 *10:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*10:01",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926309"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448926119,
              "Variant/Haplotypes": "HLA-B*39:05",
              "Gene": "HLA-B",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
              "Sentence": "HLA-B *39:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
              "Alleles": "*39:05",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1448926119"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1449155757,
              "Variant/Haplotypes": "rs28399499",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "The authors analyze rs28399499 T>C and rs3745274 G>A/T together as \"slow metabolizer\" genotypes.",
              "Sentence": "Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.",
              "Alleles": "C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "T",
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1449155757"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1449155771,
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 28819312,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "The authors analyze rs28399499 T>C and rs3745274 G>A/T together as \"slow metabolizer\" genotypes.",
              "Sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.",
              "Alleles": "T",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "G",
              "Comparison Metabolizer types": null,
              "PMID_norm": "28819312",
              "Variant Annotation ID_norm": "1449155771"
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "functional_analysis": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "study_parameters": {
      "score": 0.7832135587330012,
      "total_samples": 43,
      "ground_truth_annotations": {
        "count": 43,
        "matched_count": 43,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.8739825592321508,
            "annotation": {
              "Study Parameters ID": 1448926231,
              "Variant Annotation ID": 1448926229,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926231,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926229,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort multivariate model; carriage of protective HLA-B alleles (B*15:01/12/24/25/27/32/35, B*52:01) vs non-carriage",
                "score": 0.8577035069465637,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.18,
                "prediction": 0.18,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.07,
                "prediction": 0.07,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.46,
                "prediction": 0.46,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8736847288468305,
            "annotation": {
              "Study Parameters ID": 1448926057,
              "Variant Annotation ID": 1448926055,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926057,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926055,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort multivariate model; carriage of risk B07-group HLA-B alleles (B*35:05, B*39:10, B*51:01/02, B*54:01, B*55:01/02, B*56:01/04, B*67:01, B*78:01) vs non-carriage",
                "score": 0.8526403903961182,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 2.32,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 1.42,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 3.79,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8735565087374519,
            "annotation": {
              "Study Parameters ID": 1448925915,
              "Variant Annotation ID": 1448925913,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925915,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925913,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort multivariate model; carriage of other HLA-C risk F-pocket cluster alleles (C*04:03/06/07, C*05:01/09, C*18:01) vs non-carriage",
                "score": 0.8504606485366821,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.91,
                "prediction": 2.91,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.62,
                "prediction": 1.62,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.23,
                "prediction": 5.23,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8733026665799758,
            "annotation": {
              "Study Parameters ID": 1448926111,
              "Variant Annotation ID": 1448926109,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926111,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926109,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort multivariate model; carriage of non-B07 risk HLA-B alleles (B*13:02, B*38:01/02, B*39:01/05/06/09, B*51:07) vs non-carriage",
                "score": 0.8461453318595886,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.76,
                "prediction": 1.76,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.02,
                "prediction": 1.02,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.02,
                "prediction": 3.02,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8730306064381319,
            "annotation": {
              "Study Parameters ID": 1448926301,
              "Variant Annotation ID": 1448926299,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926301,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926299,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843",
                "prediction": "Whole cohort multivariate model; carriage of risk HLA-DRB1 alleles (DRB1*01:01/02/03, DRB1*04:04/05/08/10) vs non-carriage",
                "score": 0.8415203094482422,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.0,
                "prediction": 2.0,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.23,
                "prediction": 1.23,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.24,
                "prediction": 3.24,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8139011018416461,
            "annotation": {
              "Study Parameters ID": 1448925872,
              "Variant Annotation ID": 1448925862,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 1.0E-4",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 4.06,
              "Confidence Interval Start": 2.39,
              "Confidence Interval Stop": 6.88,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925872,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925862,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843",
                "prediction": "Whole cohort multivariate logistic regression; carriage of HLA-C*04:01 vs non-carriage; model includes other HLA risk/protective clusters and CYP2B6 metabolizer status",
                "score": 0.8363187313079834,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 1.0E-4",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 4.06,
                "prediction": 4.06,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 2.39,
                "prediction": 2.39,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 6.88,
                "prediction": 6.88,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7973617883289561,
            "annotation": {
              "Study Parameters ID": 1448926101,
              "Variant Annotation ID": 1448926099,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926101,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926099,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster group B*38;*39 vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8551504015922546,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.04",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.76,
                "prediction": 1.82,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.02,
                "prediction": 1.02,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.02,
                "prediction": 3.22,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7966560868655934,
            "annotation": {
              "Study Parameters ID": 1448926291,
              "Variant Annotation ID": 1448926289,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926291,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926289,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843",
                "prediction": "Whole cohort; MHCcluster group B*51;*54;*55;*56 vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8431534767150879,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.003",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.0,
                "prediction": 2.09,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.23,
                "prediction": 1.29,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.24,
                "prediction": 3.39,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.790640335223254,
            "annotation": {
              "Study Parameters ID": 1448926271,
              "Variant Annotation ID": 1448926269,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926271,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926269,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843",
                "prediction": "Whole cohort; MHCcluster group B*35;*53 vs non-carriage; adjusted for race only",
                "score": 0.8408856987953186,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.003",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.0,
                "prediction": 2.09,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.23,
                "prediction": 1.28,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.24,
                "prediction": 3.41,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7382803916931152,
            "annotation": {
              "Study Parameters ID": 1448926091,
              "Variant Annotation ID": 1448926089,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926091,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926089,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster group B*51;*54;*55;*56 vs non-carriage; adjusted for race only",
                "score": 0.850766658782959,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.03",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.76,
                "prediction": 1.66,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.02,
                "prediction": 1.05,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.02,
                "prediction": 2.63,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.737667203650755,
            "annotation": {
              "Study Parameters ID": 1448926281,
              "Variant Annotation ID": 1448926279,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926281,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926279,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843",
                "prediction": "Whole cohort multivariate model; slow CYP2B6 metabolizer genotype vs extensive/normal metabolizer; association with cutaneous nevirapine hypersensitivity",
                "score": 0.8403424620628357,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.0,
                "prediction": 2.07,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.23,
                "prediction": 1.12,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.24,
                "prediction": 3.82,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7322584061061634,
            "annotation": {
              "Study Parameters ID": 1448926141,
              "Variant Annotation ID": 1448926139,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926141,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926139,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; HLA-B07 supertype vs non-carriage; model adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.848392903804779,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.01",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.76,
                "prediction": 1.64,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.02,
                "prediction": 1.11,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.02,
                "prediction": 2.44,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6973964852445266,
            "annotation": {
              "Study Parameters ID": 1448926241,
              "Variant Annotation ID": 1448926239,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926241,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926239,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; presence of protective HLA-B B pocket motif (HLA-B B62 supertype cluster: HLA-B*15:01/12/24/25/27/32/35 and B*52:01) vs non-carriage; ethnicity-adjusted logistic regression without adjustment for HLA-C risk F-pocket cluster",
                "score": 0.8557402491569519,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.0001",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.18,
                "prediction": 0.18,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.07,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.46,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6912457711556379,
            "annotation": {
              "Study Parameters ID": 1448926151,
              "Variant Annotation ID": 1448926149,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926151,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926149,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster B*18;*44 group vs non-carriage; adjusted for race only",
                "score": 0.8511781096458435,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.07",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.76,
                "prediction": 1.54,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.02,
                "prediction": 0.97,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.02,
                "prediction": 2.43,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.691039300666136,
            "annotation": {
              "Study Parameters ID": 1448926077,
              "Variant Annotation ID": 1448926075,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926077,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926075,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; HLA-B08 supertype vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8476681113243103,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.4",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.76,
                "prediction": 1.39,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.02,
                "prediction": 0.67,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.02,
                "prediction": 2.92,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6904087852029239,
            "annotation": {
              "Study Parameters ID": 1448926131,
              "Variant Annotation ID": 1448926129,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926131,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926129,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; supertype-level analysis of HLA-B07 supertype vs non-carriage; ethnicity-adjusted, not adjusted for HLA-C cluster",
                "score": 0.836949348449707,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.004",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.76,
                "prediction": 1.75,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.02,
                "prediction": 1.19,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.02,
                "prediction": 2.58,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6862288390888888,
            "annotation": {
              "Study Parameters ID": 1448925905,
              "Variant Annotation ID": 1448925903,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925905,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925903,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Carriage of HLA-C*04:01 vs non-carriage in whole cohort of nevirapine-treated HIV-1 patients with severe cutaneous hypersensitivity (grade 3/4 rash)",
                "score": 0.8658902645111084,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.0001",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.91,
                "prediction": 3.06,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.62,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.23,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6852919732823092,
            "annotation": {
              "Study Parameters ID": 1448926171,
              "Variant Annotation ID": 1448926169,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926171,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926169,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster B*52 group vs non-carriage; adjusted for race only",
                "score": 0.8499635457992554,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.1",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.18,
                "prediction": 0.19,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.07,
                "prediction": 0.03,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.46,
                "prediction": 1.48,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6388010873514063,
            "annotation": {
              "Study Parameters ID": 1448926067,
              "Variant Annotation ID": 1448926065,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926067,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926065,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster group B*57;*58 vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8596184849739075,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.4",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 0.78,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 0.44,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 1.39,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6387533931171193,
            "annotation": {
              "Study Parameters ID": 1448925994,
              "Variant Annotation ID": 1448925992,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925994,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925992,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; HLA-B44 supertype vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8588076829910278,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.7",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 0.92,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 0.61,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 1.38,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6387118381612441,
            "annotation": {
              "Study Parameters ID": 1448926047,
              "Variant Annotation ID": 1448926045,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926047,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926045,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; multivariable model including imputed HLA-C expression and carriage of any risk HLA-C F-pocket cluster allele (HLA-C*04:01/03/06, C*05:01/09, C*18:01) vs non-carriage; association with cutaneous nevirapine hypersensitivity",
                "score": 0.8581012487411499,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.0001",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6386762997683357,
            "annotation": {
              "Study Parameters ID": 1448925984,
              "Variant Annotation ID": 1448925982,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925984,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925982,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster B*18;*44 group vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8574970960617065,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.5",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 1.16,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 0.72,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 1.89,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6386499650338117,
            "annotation": {
              "Study Parameters ID": 1448925974,
              "Variant Annotation ID": 1448925972,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925974,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925972,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster B*52 group vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8570494055747986,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.2",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 0.22,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 0.03,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 1.73,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6386432507458855,
            "annotation": {
              "Study Parameters ID": 1448926037,
              "Variant Annotation ID": 1448926035,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926037,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926035,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster group B*57;*58 vs non-carriage; adjusted for race only",
                "score": 0.8569352626800537,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.4",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 0.79,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 0.45,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 1.39,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6385320705526015,
            "annotation": {
              "Study Parameters ID": 1448925960,
              "Variant Annotation ID": 1448925958,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925960,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925958,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster group B*35;*53 vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8550451993942261,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.4",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 1.25,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 0.73,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 2.16,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6385179512641009,
            "annotation": {
              "Study Parameters ID": 1448926161,
              "Variant Annotation ID": 1448926159,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926161,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926159,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; HLA-B62 supertype vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8548051714897156,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.009",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.18,
                "prediction": 0.49,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.07,
                "prediction": 0.29,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.46,
                "prediction": 0.83,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6385070401079515,
            "annotation": {
              "Study Parameters ID": 1448926211,
              "Variant Annotation ID": 1448926209,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926211,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926209,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; presence of protective HLA-B B pocket motif (HLA-B B62 supertype cluster: HLA-B*15:01/12/24/25/27/32/35 and B*52:01) vs non-carriage; model additionally adjusted for HLA-C risk F-pocket cluster",
                "score": 0.8546196818351746,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.0003",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.18,
                "prediction": 0.2,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.07,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.46,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6384869884042179,
            "annotation": {
              "Study Parameters ID": 1448998277,
              "Variant Annotation ID": 1448998275,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448998277,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448998275,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster group B*46 vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8542788028717041,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.7",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 1.12,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 0.56,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 2.25,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6384661548277911,
            "annotation": {
              "Study Parameters ID": 1448925885,
              "Variant Annotation ID": 1448925883,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925885,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925883,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster B*37;*40;*45;*50 group vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8539246320724487,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.1",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.91,
                "prediction": 0.67,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.62,
                "prediction": 0.39,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.23,
                "prediction": 1.13,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6384252204614527,
            "annotation": {
              "Study Parameters ID": 1448925895,
              "Variant Annotation ID": 1448925893,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925895,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925893,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster B*07 group vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.853228747844696,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.3",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.91,
                "prediction": 0.69,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.62,
                "prediction": 0.34,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.23,
                "prediction": 1.41,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6384115534670213,
            "annotation": {
              "Study Parameters ID": 1448926024,
              "Variant Annotation ID": 1448926022,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926024,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926022,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; HLA-B58 supertype vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8529964089393616,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.2",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 0.68,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 0.39,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 1.19,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.638327468844021,
            "annotation": {
              "Study Parameters ID": 1448926014,
              "Variant Annotation ID": 1448926012,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926014,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926012,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster group B*38;*39 vs non-carriage; adjusted for race only",
                "score": 0.8515669703483582,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.2",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 1.5,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 0.86,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 2.61,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6383257929016563,
            "annotation": {
              "Study Parameters ID": 1448926201,
              "Variant Annotation ID": 1448926199,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926201,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926199,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster group B*14 vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8515384793281555,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.3",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.18,
                "prediction": 0.64,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.07,
                "prediction": 0.26,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.46,
                "prediction": 1.57,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6383116034900441,
            "annotation": {
              "Study Parameters ID": 1448925875,
              "Variant Annotation ID": 1448925873,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925875,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925873,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster B*27 group vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8512972593307495,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.4",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.91,
                "prediction": 0.68,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.62,
                "prediction": 0.27,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.23,
                "prediction": 1.74,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6383070489939522,
            "annotation": {
              "Study Parameters ID": 1448926004,
              "Variant Annotation ID": 1448926002,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.32,
              "Confidence Interval Start": 1.42,
              "Confidence Interval Stop": 3.79,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926004,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926002,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; HLA-B27 supertype vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8512198328971863,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.8",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.32,
                "prediction": 1.07,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.42,
                "prediction": 0.67,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.79,
                "prediction": 1.72,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6382860681589912,
            "annotation": {
              "Study Parameters ID": 1448926251,
              "Variant Annotation ID": 1448926249,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926251,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926249,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster B*13 group vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8508631587028503,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.7",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.18,
                "prediction": 1.12,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.07,
                "prediction": 0.62,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.46,
                "prediction": 2.05,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6382384545662824,
            "annotation": {
              "Study Parameters ID": 1448926121,
              "Variant Annotation ID": 1448926119,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.76,
              "Confidence Interval Start": 1.02,
              "Confidence Interval Stop": 3.02,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926121,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926119,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; MHCcluster B*15 group vs non-carriage; adjusted for race and predisposing HLA-C*04:01 cluster",
                "score": 0.8500537276268005,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.001",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.76,
                "prediction": 0.4,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.02,
                "prediction": 0.23,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.02,
                "prediction": 0.7,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6381995642886442,
            "annotation": {
              "Study Parameters ID": 1448925925,
              "Variant Annotation ID": 1448925923,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.91,
              "Confidence Interval Start": 1.62,
              "Confidence Interval Stop": 5.23,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448925925,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448925923,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; HLA-B44 supertype vs non-carriage; adjusted for race only",
                "score": 0.8493925929069519,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.9",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.91,
                "prediction": 1.02,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.62,
                "prediction": 0.69,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.23,
                "prediction": 1.51,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6381889441434074,
            "annotation": {
              "Study Parameters ID": 1448926181,
              "Variant Annotation ID": 1448926179,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.07,
              "Confidence Interval Stop": 0.46,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926181,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926179,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843)",
                "prediction": "Whole cohort; HLA-B62 supertype vs non-carriage; adjusted for race only",
                "score": 0.8492120504379272,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.004",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.18,
                "prediction": 0.47,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.07,
                "prediction": 0.28,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.46,
                "prediction": 0.79,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6375095388468575,
            "annotation": {
              "Study Parameters ID": 1448926261,
              "Variant Annotation ID": 1448926259,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926261,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926259,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843",
                "prediction": "Whole cohort; MHCcluster group B*46 vs non-carriage; adjusted for race only",
                "score": 0.8376621603965759,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "> 0.9",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.0,
                "prediction": 0.98,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.23,
                "prediction": 0.49,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.24,
                "prediction": 1.94,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6374758937779594,
            "annotation": {
              "Study Parameters ID": 1448926311,
              "Variant Annotation ID": 1448926309,
              "Study Type": "case/control",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.23,
              "Confidence Interval Stop": 3.24,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448926311,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448926309,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 151,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 413,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "NCT00310843",
                "prediction": "Whole cohort; MHCcluster B*37;*40;*45;*50 group vs non-carriage; adjusted for race only",
                "score": 0.8370901942253113,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "= 0.05",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.0,
                "prediction": 0.6,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.23,
                "prediction": 0.36,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.24,
                "prediction": 1.01,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5610262898837819,
            "annotation": {
              "Study Parameters ID": 1449155766,
              "Variant Annotation ID": 1449155757,
              "Study Type": "case/control, clinical trial",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "Study Cohort: NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.07,
              "Confidence Interval Start": 1.12,
              "Confidence Interval Stop": 3.82,
              "Biogeographical Groups": "Unknown"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1449155766,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1449155757,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control, clinical trial",
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 65,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 257,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "Study Cohort: NCT00310843",
                "prediction": "Asian multivariate model; carriage of risk B07-group HLA-B alleles vs non-carriage",
                "score": 0.837446928024292,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.07,
                "prediction": 2.19,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.12,
                "prediction": 1.1,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.82,
                "prediction": 4.35,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5563308267032399,
            "annotation": {
              "Study Parameters ID": 1449155773,
              "Variant Annotation ID": 1449155771,
              "Study Type": "case/control, clinical trial",
              "Study Cases": 151.0,
              "Study Controls": 413.0,
              "Characteristics": "Study Cohort: NCT00310843",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.07,
              "Confidence Interval Start": 1.12,
              "Confidence Interval Stop": 3.82,
              "Biogeographical Groups": "Unknown"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1449155773,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1449155771,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case/control, clinical trial",
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 151.0,
                "prediction": 42,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": 413.0,
                "prediction": 158,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "Study Cohort: NCT00310843",
                "prediction": "Caucasian multivariate model; carriage of risk B07-group HLA-B alleles vs non-carriage",
                "score": 0.8576240539550781,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.07,
                "prediction": 2.27,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.12,
                "prediction": 1.06,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.82,
                "prediction": 4.85,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "European",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 33,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 65,
              "Study Controls": 257,
              "Characteristics": "Asian ancestry subgroup; carriage of HLA-C*04:01 vs non-carriage among nevirapine-treated HIV-1 patients with severe cutaneous hypersensitivity (grade 3/4 rash)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.0001",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 5.49,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 67,
              "Study Controls": 244,
              "Characteristics": "Caucasian ancestry subgroup (European and Hispanic combined); carriage of HLA-C*04:01 vs non-carriage among nevirapine-treated HIV-1 patients with severe cutaneous hypersensitivity (grade 3/4 rash)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.02",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.08,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 19,
              "Study Controls": 63,
              "Characteristics": "African ancestry subgroup (African American); carriage of HLA-C*04:01 vs non-carriage among nevirapine-treated HIV-1 patients with severe cutaneous hypersensitivity (grade 3/4 rash)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.04",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 3.84,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 67,
              "Study Controls": 244,
              "Characteristics": "Caucasian ancestry subgroup; carriage of HLA-C*05:01 vs non-carriage among nevirapine-treated HIV-1 patients with severe cutaneous hypersensitivity (grade 3/4 rash)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.002",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.84,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 19,
              "Study Controls": 63,
              "Characteristics": "African ancestry subgroup; carriage of HLA-C*18:01 vs non-HLA-C*18:01 carriers among nevirapine-treated HIV-1 patients with severe cutaneous hypersensitivity (grade 3/4 rash)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.2",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.67,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 19,
              "Study Controls": 63,
              "Characteristics": "African ancestry subgroup; carriage of HLA-C*18:01 vs non-carriage of HLA-C*04:01 or HLA-C*18:01 among nevirapine-treated HIV-1 patients with severe cutaneous hypersensitivity (grade 3/4 rash)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.06",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 4.71,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 151,
              "Study Controls": 413,
              "Characteristics": "Whole cohort; multivariable model including imputed HLA-C expression and carriage of HLA-C risk F-pocket cluster allele (HLA-C*04:01/03/06, C*05:01/09, C*18:01); effect of HLA-C expression level (MFI) on cutaneous nevirapine hypersensitivity",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "> 0.2",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 151,
              "Study Controls": 413,
              "Characteristics": "Whole cohort; HLA-B08 supertype vs non-carriage; adjusted for race only",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "> 0.9",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.98,
              "Confidence Interval Start": 0.48,
              "Confidence Interval Stop": 2.0,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 151,
              "Study Controls": 413,
              "Characteristics": "Whole cohort; HLA-B27 supertype vs non-carriage; adjusted for race only",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "> 0.9",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 0.63,
              "Confidence Interval Stop": 1.58,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 151,
              "Study Controls": 413,
              "Characteristics": "Whole cohort; HLA-B58 supertype vs non-carriage; adjusted for race only",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.2",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.68,
              "Confidence Interval Start": 0.39,
              "Confidence Interval Stop": 1.18,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 151,
              "Study Controls": 413,
              "Characteristics": "Whole cohort; MHCcluster B*07 group vs non-carriage; adjusted for race only",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.07",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.53,
              "Confidence Interval Start": 0.26,
              "Confidence Interval Stop": 1.06,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 151,
              "Study Controls": 413,
              "Characteristics": "Whole cohort; MHCcluster group B*14 vs non-carriage; adjusted for race only",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.3",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.65,
              "Confidence Interval Start": 0.27,
              "Confidence Interval Stop": 1.57,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 151,
              "Study Controls": 413,
              "Characteristics": "Whole cohort; MHCcluster B*15 group vs non-carriage (subset of B62 supertype); adjusted for race only",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.002",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.43,
              "Confidence Interval Start": 0.25,
              "Confidence Interval Stop": 0.74,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 151,
              "Study Controls": 413,
              "Characteristics": "Whole cohort; MHCcluster B*13 group vs non-carriage; adjusted for race only",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.6",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.15,
              "Confidence Interval Start": 0.64,
              "Confidence Interval Stop": 2.07,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 151,
              "Study Controls": 413,
              "Characteristics": "Whole cohort; MHCcluster B*27 group vs non-carriage; adjusted for race only",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.4",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.69,
              "Confidence Interval Start": 0.27,
              "Confidence Interval Stop": 1.73,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 42,
              "Study Controls": 158,
              "Characteristics": "Caucasian ancestry multivariate model; carriage of HLA-C*04:01 vs non-carriage; model includes other HLA risk/protective clusters and CYP2B6 metabolizer status",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 3.14,
              "Confidence Interval Start": 1.49,
              "Confidence Interval Stop": 6.62,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 65,
              "Study Controls": 257,
              "Characteristics": "Asian ancestry multivariate model; carriage of HLA-C*04:01 vs non-carriage; model includes other HLA risk/protective clusters and CYP2B6 metabolizer status",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 7.3,
              "Confidence Interval Start": 2.74,
              "Confidence Interval Stop": 19.5,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 19,
              "Study Controls": 63,
              "Characteristics": "African ancestry multivariate model; carriage of HLA-C*04:01 vs non-carriage; model includes other HLA risk/protective clusters and CYP2B6 metabolizer status",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 5.6,
              "Confidence Interval Start": 1.22,
              "Confidence Interval Stop": 25.75,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 42,
              "Study Controls": 158,
              "Characteristics": "Caucasian multivariate model; carriage of other HLA-C risk F-pocket cluster alleles (C*04:03/06/07, C*05:01/09, C*18:01) vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 3.92,
              "Confidence Interval Start": 1.74,
              "Confidence Interval Stop": 8.86,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 65,
              "Study Controls": 257,
              "Characteristics": "Asian multivariate model; carriage of other HLA-C risk F-pocket cluster alleles (C*04:03/06/07, C*05:01/09, C*18:01) vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.64,
              "Confidence Interval Start": 0.53,
              "Confidence Interval Stop": 5.12,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 19,
              "Study Controls": 63,
              "Characteristics": "African multivariate model; carriage of other HLA-C risk F-pocket cluster alleles (C*04:03/06/07, C*05:01/09, C*18:01) vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 3.18,
              "Confidence Interval Start": 0.53,
              "Confidence Interval Stop": 19.04,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 19,
              "Study Controls": 63,
              "Characteristics": "African multivariate model; carriage of risk B07-group HLA-B alleles vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.93,
              "Confidence Interval Start": 0.23,
              "Confidence Interval Stop": 37.1,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 42,
              "Study Controls": 158,
              "Characteristics": "Caucasian multivariate model; carriage of non-B07 risk HLA-B alleles vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.87,
              "Confidence Interval Start": 0.76,
              "Confidence Interval Stop": 4.57,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 65,
              "Study Controls": 257,
              "Characteristics": "Asian multivariate model; carriage of non-B07 risk HLA-B alleles vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.5,
              "Confidence Interval Start": 0.72,
              "Confidence Interval Stop": 3.12,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 19,
              "Study Controls": 63,
              "Characteristics": "African multivariate model; carriage of non-B07 risk HLA-B alleles vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 5.54,
              "Confidence Interval Start": 0.3,
              "Confidence Interval Stop": 101.2,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 42,
              "Study Controls": 158,
              "Characteristics": "Caucasian multivariate model; carriage of protective HLA-B alleles (B*15:01/12/24/25/27/32/35, B*52:01) vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.25,
              "Confidence Interval Start": 0.06,
              "Confidence Interval Stop": 1.15,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 65,
              "Study Controls": 257,
              "Characteristics": "Asian multivariate model; carriage of protective HLA-B alleles (B*15:01/12/24/25/27/32/35, B*52:01) vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.18,
              "Confidence Interval Start": 0.05,
              "Confidence Interval Stop": 0.61,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 42,
              "Study Controls": 158,
              "Characteristics": "Caucasian multivariate model; carriage of risk HLA-DRB1 alleles (DRB1*01:01/02/03, DRB1*04:04/05/08/10) vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.34,
              "Confidence Interval Start": 0.68,
              "Confidence Interval Stop": 2.64,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 65,
              "Study Controls": 257,
              "Characteristics": "Asian multivariate model; carriage of risk HLA-DRB1 alleles (DRB1*01:01/02/03, DRB1*04:04/05/08/10) vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 3.23,
              "Confidence Interval Start": 1.4,
              "Confidence Interval Stop": 7.43,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 19,
              "Study Controls": 63,
              "Characteristics": "African multivariate model; carriage of risk HLA-DRB1 alleles (DRB1*01:01/02/03, DRB1*04:04/05/08/10) vs non-carriage",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 4.77,
              "Confidence Interval Start": 0.95,
              "Confidence Interval Stop": 24.04,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 42,
              "Study Controls": 158,
              "Characteristics": "Caucasian multivariate model; slow CYP2B6 metabolizer genotype vs extensive/normal metabolizer",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 3.19,
              "Confidence Interval Start": 1.04,
              "Confidence Interval Stop": 9.78,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 65,
              "Study Controls": 257,
              "Characteristics": "Asian multivariate model; slow CYP2B6 metabolizer genotype vs extensive/normal metabolizer",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.66,
              "Confidence Interval Start": 0.64,
              "Confidence Interval Stop": 4.32,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 19,
              "Study Controls": 63,
              "Characteristics": "African multivariate model; slow CYP2B6 metabolizer genotype vs extensive/normal metabolizer",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.81,
              "Confidence Interval Start": 0.45,
              "Confidence Interval Stop": 7.33,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}